Takeda tanks on falling revenue

30 October 2020

Shares in Japanese drugmaker Takeda (TYO: 4502) slipped by 6% on Friday after the firm presented its latest financial results.

Since Takeda’s financial year runs from April to March, the figures relate to the first half of the fiscal year, which has of course been hit by the challenges of the COVID-19 pandemic.

Revenue for the six months to end September 2020, has dropped by 4.2% to 1,590.8 billion yen ($15.23 billion) compared to the same period a year ago, and Takeda has revised down its sales guidance for the year from 3,250 billion yen to 3,200 billion yen. The company blamed this primarily on the impact of foreign exchange.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK